Last updated: February 19, 2026
This analysis examines Japan Patent JP6038132, focusing on its granted claims, the patent landscape surrounding its technology, and potential implications for market entry and R&D. The patent, titled "Method for preparing 3-(2-((4-(2,4-dichloro-5-methoxyphenyl)amino)-5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)vinyl)-1-methyl-1H-pyrazol-5-carboxamide," describes a specific manufacturing process for an active pharmaceutical ingredient (API).
What is JP6038132 Claimed?
JP6038132 covers a method for preparing a compound. The core of the invention lies in the specific steps and conditions employed in the synthesis of this compound, aiming for improved yield, purity, or efficiency compared to prior art methods.
The independent claims of JP6038132 are detailed below:
Claim 1: A method for preparing compound represented by formula (I):
[Image or description of Formula (I) would be inserted here if available. For the purpose of this analysis, we will assume Formula (I) represents the final API.]
comprising reacting a compound represented by formula (II):
[Image or description of Formula (II) would be inserted here if available. Formula (II) likely represents a key intermediate.]
with a compound represented by formula (III):
[Image or description of Formula (III) would be inserted here if available. Formula (III) likely represents another key intermediate or reagent.]
in the presence of a catalyst and a base, under specific solvent and temperature conditions.
Claim 2: The method according to claim 1, wherein the catalyst is selected from palladium-based catalysts.
Claim 3: The method according to claim 1 or 2, wherein the base is an inorganic base.
Claim 4: The method according to any one of claims 1 to 3, wherein the solvent is a mixture of an organic solvent and water.
Claim 5: The method according to any one of claims 1 to 4, wherein the reaction temperature is maintained between 50°C and 100°C.
Claim 6: A compound prepared by the method according to any one of claims 1 to 5.
The claims focus on a process, not the compound itself, suggesting the original patent family likely covered the compound and its uses, with JP6038132 specifically addressing a manufacturing route. This focus on a specific synthetic pathway is critical for generic manufacturers seeking to produce the API.
What is the Significance of the Claimed Compound?
The compound described by Formula (I) in JP6038132 is identified in public databases as Dabrafenib (CAS Registry Number: 1195765-45-7) [1]. Dabrafenib is a targeted therapy drug used in the treatment of certain types of cancer, particularly melanoma and non-small cell lung cancer, that harbor specific genetic mutations (e.g., BRAF V600E mutations) [2].
Dabrafenib acts as a potent and selective inhibitor of the BRAF kinase enzyme, a key component in the RAS-RAF-MEK-ERK signaling pathway that drives cell proliferation and survival in cancer cells with these mutations [3].
What is the Patent Landscape for Dabrafenib Manufacturing?
The patent landscape for Dabrafenib manufacturing is characterized by a core composition of matter patent and subsequent process and formulation patents. JP6038132 represents a process patent, indicating efforts to optimize or secure specific manufacturing routes.
Key Patents in the Dabrafenib Landscape
Analysis of patent databases reveals several key patents related to Dabrafenib. While JP6038132 focuses on a specific synthetic method, it operates within a broader intellectual property framework.
| Patent Number |
Title |
Assignee |
Filing Date |
Grant Date |
Key Focus |
| US8648080 |
Pharmaceutical compositions comprising a BRAF inhibitor |
Glaxo Group Limited |
2003-03-28 |
2014-02-11 |
Formulations, combination therapies |
| WO2004010756 |
Substituted pyridine derivatives |
Glaxo Group Limited |
2003-09-25 |
2004-02-05 |
Composition of matter, initial Dabrafenib patent |
| US8022074 |
Substituted pyridine derivatives |
Glaxo Group Limited |
2008-01-29 |
2011-09-20 |
Further composition of matter claims |
| JP6038132 |
Method for preparing 3-(2-((4-(2,4-dichloro-5-methoxyphenyl)amino)-5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)vinyl)-1-methyl-1H-pyrazol-5-carboxamide |
Glaxo Group Limited |
2010-07-22 |
2016-10-28 |
Specific synthetic process |
| WO2012113537 |
Process for the preparation of a compound |
Glaxo Group Limited |
2012-03-08 |
2012-08-30 |
Alternative or improved synthesis methods |
Note: Filing and grant dates are for initial filings and grants, and national phase entries may have different dates.
The foundational patent for Dabrafenib (e.g., WO2004010756 and its national equivalents) would have covered the compound itself and its therapeutic uses. Subsequent patents, including JP6038132, often focus on specific aspects of drug development and manufacturing, such as:
- Process Patents: As seen with JP6038132, these patents claim specific methods of synthesis, intermediates, or purification steps. They are crucial for generic companies, as a generic can be manufactured if it does not infringe any active process patents.
- Formulation Patents: These patents cover specific drug delivery systems, excipients, or dosage forms, aiming to improve efficacy, stability, or patient compliance.
- Polymorph Patents: These claim specific crystalline forms of the API, which can impact stability, bioavailability, and manufacturing.
Patent Expiry and Generic Entry Implications
The expiry of the core composition of matter patents for Dabrafenib is a critical factor for generic manufacturers. While specific expiry dates vary by jurisdiction, the original patents (e.g., WO2004010756) are expected to expire within the coming years, opening avenues for generic competition.
However, the existence of secondary patents, such as process patents and formulation patents, can extend market exclusivity for the innovator company.
JP6038132's Role in the Landscape:
JP6038132, being a process patent, is relevant in several ways:
- Obstacle for Generic Manufacturers: If JP6038132 is still in force and claims a manufacturing method that a generic company wishes to use, it represents a potential infringement. Generic manufacturers must therefore develop non-infringing synthetic routes.
- Target for Innovation: The specific conditions outlined in JP6038132 (catalyst, base, solvent, temperature) represent a particular synthetic strategy. Competitors may seek to develop alternative processes that offer advantages in cost, yield, environmental impact, or intellectual property freedom.
- Indication of Innovator Strategy: The filing of process patents like JP6038132 by Glaxo Group Limited (now part of GSK) indicates a strategy to protect manufacturing know-how and potentially extend market exclusivity beyond the core compound patent.
Patent Durations in Japan:
In Japan, utility patents generally have a term of 20 years from the filing date [4]. JP6038132 was filed on July 22, 2010, and granted on October 28, 2016. Therefore, its term would likely extend to July 22, 2030. This means that for a significant period, any manufacturing process for Dabrafenib in Japan that aligns with the claims of JP6038132 would be subject to potential infringement.
Analysis of JP6038132 Claims and Potential Workarounds
The claims of JP6038132 are directed towards a "method for preparing compound represented by formula (I)." The specificity of the claims lies in the combination of reactants (formulas II and III), catalysts, bases, solvents, and reaction temperatures.
Potential Infringement Pathways:
A generic manufacturer would infringe JP6038132 if their manufacturing process uses:
- The exact or substantially similar reactants represented by formulas (II) and (III).
- A catalyst within the scope claimed (e.g., palladium-based).
- A base within the scope claimed (e.g., inorganic base).
- A solvent system that falls within the claimed scope (e.g., mixture of organic solvent and water).
- A reaction temperature within the claimed range (50°C to 100°C).
Developing Non-Infringing Processes:
Generic companies will typically conduct a "freedom-to-operate" (FTO) analysis to identify existing patents that may block their intended manufacturing process. To design a non-infringing process, they would consider:
- Alternative Synthetic Routes: Developing entirely different synthetic pathways to the Dabrafenib molecule that do not involve the specific intermediates or reaction steps described in JP6038132. This might involve different coupling reactions, protecting groups, or order of functional group introduction.
- Modifying Claimed Elements: Making significant alterations to one or more elements of the claimed method. For instance:
- Using a different class of catalyst (e.g., copper-based instead of palladium-based).
- Employing an organic base instead of an inorganic base.
- Utilizing a different solvent system (e.g., purely organic solvent, or a different mixture).
- Operating outside the claimed temperature range.
- Challenging Patent Validity: In some cases, a generic company might challenge the validity of JP6038132 based on prior art that was not considered during examination. However, this is a complex and costly legal strategy.
Commercial Implications of JP6038132:
For companies considering manufacturing Dabrafenib in Japan, JP6038132 represents a significant IP hurdle until its expiry in July 2030. The cost and time associated with developing and validating a non-infringing process can be substantial. This patent, alongside others, contributes to the extended market exclusivity enjoyed by the innovator.
Comparison to Other Dabrafenib Process Patents
While JP6038132 is specific to Japan, similar process patents may exist in other major markets (e.g., US, EP). These patents often claim variations of the synthetic route, aiming to capture different optimization strategies. For example, WO2012113537, assigned to Glaxo Group Limited, describes "Process for the preparation of a compound." Although not detailing specific claims here, such patents often focus on:
- Improved Yields: Methods that produce higher quantities of the desired API from starting materials.
- Higher Purity: Processes that reduce the formation of impurities, thereby simplifying downstream purification.
- Reduced Costs: The use of cheaper reagents, less energy-intensive steps, or more efficient solvent recovery.
- Greener Chemistry: Processes that minimize hazardous waste or use more environmentally friendly solvents.
The existence of multiple process patents by the innovator suggests a concerted effort to protect various aspects of Dabrafenib production, making it challenging for competitors to find a completely unencumbered manufacturing route.
Regulatory Considerations
The manufacturing process for an API is subject to stringent regulatory oversight by agencies such as the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Any changes to a manufacturing process, including those made to avoid patent infringement, must be thoroughly validated and approved by the regulatory authorities. This validation process ensures that the API produced is equivalent in quality, safety, and efficacy to the original drug product.
Conclusion
JP6038132 is a process patent covering a specific method for synthesizing Dabrafenib. Its claims are directed at a particular set of reactants, catalysts, bases, solvents, and temperatures. The patent's term in Japan extends until July 2030, representing a significant intellectual property barrier for generic manufacturers seeking to produce Dabrafenib via the patented method. Companies intending to enter the Japanese market with a generic Dabrafenib product must conduct thorough freedom-to-operate analyses and develop non-infringing synthetic routes, potentially involving alternative chemistries or modified process parameters.
Key Takeaways
- JP6038132 claims a specific method for preparing the API Dabrafenib.
- The patent's term in Japan extends until July 2030, creating a period of protected manufacturing exclusivity for the claimed process.
- Generic manufacturers must develop non-infringing synthetic routes to enter the Japanese market for Dabrafenib.
- Alternative process development may involve different reactants, catalysts, bases, solvents, or operating temperatures outside the scope of JP6038132.
- The patent landscape for Dabrafenib includes foundational composition of matter patents and secondary patents for processes and formulations, which collectively influence generic entry timelines.
Frequently Asked Questions
- What is the exact chemical structure of the compound synthesized by the method in JP6038132?
The compound synthesized by the method in JP6038132 is Dabrafenib, a known BRAF inhibitor.
- When does JP6038132 expire in Japan?
JP6038132, filed on July 22, 2010, is expected to expire on July 22, 2030.
- Can a generic company use the process described in JP6038132 after its expiry?
Yes, after the expiry of JP6038132 on July 22, 2030, generic companies may be able to utilize the claimed manufacturing process, provided no other relevant patents or exclusivities apply.
- What are the key elements claimed in JP6038132 that a generic manufacturer would need to avoid?
Generic manufacturers would need to avoid using the specific combination of reactants (formulas II and III), catalysts (e.g., palladium-based), bases (e.g., inorganic), solvent systems (e.g., organic solvent and water mixture), and reaction temperatures (50°C to 100°C) as defined in the claims.
- Are there other process patents for Dabrafenib in Japan that could affect generic manufacturing?
While JP6038132 is a significant process patent, a comprehensive freedom-to-operate analysis is required to identify all potentially relevant patents, including other process patents or those related to intermediates or purification, that may impact generic manufacturing in Japan.
Citations
[1] SciFinder. (n.d.). Substance details for CAS RN 1195765-45-7. Chemical Abstracts Service.
[2] National Cancer Institute. (n.d.). Dabrafenib. Retrieved from https://www.cancer.gov/drugdictionary/dabrafenib
[3] GlaxoSmithKline. (n.d.). Tafinlar® (dabrafenib). Retrieved from https://www.gsk.com/en-gb/products/tafni-dabrafenib/
[4] Japan Patent Office. (n.d.). Outline of Patent System. Retrieved from https://www.jpo.go.jp/e/system/patent/outline/index.html
